Reviva Pharmaceuticals Q1 net loss narrows on lower expenses

Reviva Pharmaceuticals Holdings

13/05/2026 21:42

Overview

U.S. biopharma firm's Q1 net loss narrowed yr/yr on lower operating expenses

Company raised $10 mln in public equity offering during March 2026

Stock to move from Nasdaq to OTCQB Venture Market on May 14, 2026

Outlook

Reviva expects FDA feedback on new brilaroxazine formulation strategy in mid-2026

Company plans to begin patient enrollment in RECOVER-2 Phase 3 trial in Q3 2026

Reviva pursuing partnership opportunities for pipeline development

Result Drivers

LOWER OPERATING EXPENSES - Net loss narrowed mainly due to reduced research and development and general and administrative spending

Company press release: ID:nGNX6PdgsP

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.46
Q1 Net Income
-$3.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $30.00, about 3,671.7% above its May 12 closing price of $0.80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)